Common Side Effects and Their Frequency
Cosentyx (secukinumab) side effects vary by indication (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis) and are reported from clinical trials and post-marketing data. In trials for plaque psoriasis, upper respiratory infections occurred in 14-18% of patients versus 11-13% on placebo. Diarrhea affected 4-11%, while oral herpes was seen in 1-3%.[1][2]
For psoriatic arthritis, nasopharyngitis hit 16-19%, diarrhea 10-11%, and upper respiratory tract infections 8-10%.[1]
Rates drop for rarer events like serious infections (1-2%) or inflammatory bowel disease exacerbations (under 1%). Most are mild to moderate and resolve without stopping treatment.[2]
How Often Do Serious Side Effects Happen?
Serious infections, including tuberculosis reactivation, occur in about 1-2% of patients across trials, higher in those with risk factors like immunosuppression.[1][2] Candida infections affect 1-3%, mostly oral or esophageal.[1]
Hypersensitivity reactions (e.g., rash, urticaria) are rare at <1%, and anaphylaxis is even less common, reported in post-marketing surveillance.[2] Increased inflammatory bowel disease risk is low (0.1-0.4%), but monitoring is advised.[1]
No increased malignancy risk in trials up to 5 years.[2]
Side Effects by Dosage and Duration
Loading doses (300 mg weekly for 5 weeks) raise short-term infection risk slightly higher than maintenance (300 mg monthly).[1] Long-term data (up to 5 years) show stable rates: infections around 10-20% annually, but serious ones remain <2%.[2]
Subcutaneous injection site reactions occur in 2-5% initially, fading over time.[1]
Who Gets Side Effects Most Often?
Higher rates in patients over 65 (infections up to 25%) or with comorbidities like diabetes. Pediatric psoriasis trials show similar profiles to adults, with infections at 14%.[1][2] No major differences by sex or ethnicity in trials.[2]
Managing and Reporting Side Effects
Most resolve without intervention; discontinue if severe infections or IBD symptoms appear. FDA labels emphasize TB screening pre-treatment.[2] Real-world data aligns with trials, per post-approval studies.[1]
Patients report infections and diarrhea most frequently on platforms like Drugs.com, matching trial data.[3]
[1]: Cosentyx Prescribing Information (Novartis, FDA-approved label)
[2]: Cosentyx Clinical Trial Data Summary (Novartis)
[3]: DrugPatentWatch.com - Cosentyx Side Effects and Patents